Ongoing treatment(s)-Biological therapy Posts on Medivizor

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Posted by Medivizor on Oct 7, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of immune checkpoint inhibitors (ICIs) between randomized and real-world studies in patients with advanced non-small cell lung cancer (NSCLC) or melanoma. The data showed that ICIs were similarly effective and safe in both randomized and real-world studies for these patients. Some background...

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Posted by Medivizor on Nov 14, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new biological therapy drugs. This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy. Some background...

Evaluating the effectiveness of EGFR-TKIs first-line treatment and performance status in older patients with EGFR-mutant NSCLC.

Posted by Medivizor on Oct 31, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) first-line treatment and performance status in older patients with EGFR-mutant non-small-cell lung cancer (NSCLC). The data showed that older patients with EGFR-mutated NSCLC who received EGFR-TKI first-line treatment with a...

Clarithromycin administered daily reduces the skin-related side effects associated with panitumumab treatment for metastatic colorectal cancer.

Posted by Medivizor on Sep 5, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of preventative antibiotic treatment with clarithromycin (Biaxin) to prevent skin-related side effects associated with panitumumab (Vectibix) treatment for patients with metastatic colorectal cancer (mCRC). The data showed that clarithromycin administered daily along with a simple...

Evaluating the final effectiveness and safety outcomes of neratinib in patients with early stage HER2+/HR+ breast cancer.

Posted by Medivizor on Apr 4, 2021 in Breast cancer | 0 comments

In a nutshell This study reported the final effectiveness and safety outcomes of neratinib treatment in patients with early-stage HER2+/HR+ breast cancer. The data showed that neratinib significantly improved invasive disease-free survival in these patients who initiated treatment within 1 year of trastuzumab-based therapy. Some background...

How does durvalumab impact the treatment of unresectable stage III non-small cell lung cancer based on previous treatment?

Posted by Medivizor on Mar 14, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the outcomes of durvalumab (Imfinzi) in patients with unresectable (cannot be surgically removed) stage 3 non-small cell lung cancer (NSCLC) who received different combinations of chemoradiotherapy (CRT) previously. The authors found that the use of durvalumab improved survival in all patients previously treated...

Nivolumab improves survival in patients with non-small cell lung cancer in the long-term.

Posted by Medivizor on Feb 28, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...

Is heart monitoring needed in patients with HER2-positive metastatic breast cancer using trastuzumab?

Posted by Medivizor on Feb 20, 2021 in Breast cancer | 0 comments

In a nutshell This article looked at the occurrence of heart-related side effects in patients with HER2-positive metastatic breast cancer (mBC) receiving trastuzumab (Herceptin). The authors found that non-smoking patients with a good heart function before receiving treatment have a low risk of heart toxicity (HT) after 4 years...

Can tumor mutation burden be used as a predictive biomarker to immune checkpoint inhibitors for non-small cell lung cancer?

Posted by Medivizor on Feb 14, 2021 in Lung cancer | 0 comments

In a nutshell This article looked at the use of tumor mutation burden (TMB) to predict response to immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). The authors found that TMB is a promising biomarker that can predict the effectiveness of ICI therapy in advanced NSCLC. Some background NSCLC...

Evaluating the effectiveness and safety of bevacizumab biosimilar in patients with metastatic colorectal cancer

Posted by Medivizor on May 17, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of bevacizumab biosimilar (BE1040V) to the reference drug (Avastin) in the treatment of patients with metastatic colorectal cancer (mCRC). Researchers suggested that the effectiveness and safety of the biosimilar were similar to the reference drug bevacizumab. Some...

What side effects of the skin can biological therapy cause?

Posted by Medivizor on May 16, 2020 in Melanoma | 0 comments

In a nutshell This article reviewed the skin side effects caused by anti-PD-1 biological therapy. Some background Anti-PD-1 is a type of biological therapy that has significantly improved treatment results for patients with certain types of cancer. It works by blocking PD-1, a molecule that cancer cells use to switch off the immune...

Can antibiotics and proton pump inhibitors alter the effectiveness of treatment for patients with non-small cell lung cancer?

Posted by Medivizor on Apr 21, 2020 in Lung cancer | 0 comments

In a nutshell This study examined the effects of antibiotics or proton pump inhibitor (PPI) drugs on treatment for patients with non-small cell lung cancer (NSCLC). The authors found that both antibiotics and PPIs reduced the effectiveness of biological therapy but not chemotherapy. Some background Not all patients with NSCLC respond to...

Ongoing treatment(s)-Biological therapy Posts on Medivizor

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Evaluating the effectiveness of EGFR-TKIs first-line treatment and performance status in older patients with EGFR-mutant NSCLC.

Clarithromycin administered daily reduces the skin-related side effects associated with panitumumab treatment for metastatic colorectal cancer.

Evaluating the final effectiveness and safety outcomes of neratinib in patients with early stage HER2+/HR+ breast cancer.

How does durvalumab impact the treatment of unresectable stage III non-small cell lung cancer based on previous treatment?

Nivolumab improves survival in patients with non-small cell lung cancer in the long-term.

Is heart monitoring needed in patients with HER2-positive metastatic breast cancer using trastuzumab?

Can tumor mutation burden be used as a predictive biomarker to immune checkpoint inhibitors for non-small cell lung cancer?

Evaluating the effectiveness and safety of bevacizumab biosimilar in patients with metastatic colorectal cancer

What side effects of the skin can biological therapy cause?

Can antibiotics and proton pump inhibitors alter the effectiveness of treatment for patients with non-small cell lung cancer?

Categories

Recent Posts

Archives

Ongoing treatment(s)-Biological therapy Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email